Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Implementing RFID technology in a novel triage system during a simulated mass casualty situation.

Jokela J, Simons T, Kuronen P, Tammela J, Jalasvirta P, Nurmi J, Harkke V, Castrén M.

Int J Electron Healthc. 2008;4(1):105-18.

PMID:
18583298
2.

Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells.

Sharma S, Tammela J, Wang X, Arnouk H, Driscoll D, Mhawech-Fauceglia P, Lele S, Kazim AL, Odunsi K.

Clin Cancer Res. 2007 Oct 1;13(19):5889-96.

3.

OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.

Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth AA, Mhawech-Fauceglia P, Qian F, Schneider S, Sharma S, Driscoll D, Lele S, Old LJ, Nakayama E, Odunsi K.

Int J Oncol. 2006 Oct;29(4):903-10.

PMID:
16964386
4.

Gene expression and prognostic significance in ovarian cancer.

Tammela J, Odunsi K.

Minerva Ginecol. 2004 Dec;56(6):495-502. Review.

PMID:
15729202
5.

Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.

Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL.

Int J Cancer. 2005 Feb 20;113(5):782-8.

6.

SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.

Tammela J, Jungbluth AA, Qian F, Santiago D, Scanlan MJ, Keitz B, Driscoll D, Rodabaugh K, Lele S, Old LJ, Odunsi K.

Cancer Immun. 2004 Oct 18;4:10.

7.

Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up.

Odunsi K, Moneke V, Tammela J, Ghamande S, Seago P, Driscoll D, Marchetti D, Baker T, Lele S.

Int J Gynecol Cancer. 2004 Jul-Aug;14(4):659-64.

PMID:
15304162
8.

New modalities in detection of recurrent ovarian cancer.

Tammela J, Lele S.

Curr Opin Obstet Gynecol. 2004 Feb;16(1):5-9. Review.

PMID:
15128001
9.

HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.

Geisler JP, Tammela JE, Manahan KJ, Geisler HE, Miller GA, Zhou Z, Wiemann MC.

Eur J Gynaecol Oncol. 2004;25(2):165-8.

PMID:
15032273
10.

Heat shock protein 27 in the placentas of women with and without severe preeclampsia.

Geisler JP, Manahan KJ, Geisler HE, Tammela JE, Rose SL, Hiett AK, Miller GA, Wiemann MC, Zhou Z.

Clin Exp Obstet Gynecol. 2004;31(1):12-4.

PMID:
14998178
11.

Reassessment of pelvic lymph node debulking in advanced cervical cancer.

Tammela J, Bundy B, Odunsi K.

Gynecol Oncol. 2004 Mar;92(3):1014-5. No abstract available.

PMID:
14984980
12.

NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.

Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ.

Cancer Res. 2003 Sep 15;63(18):6076-83.

13.

A human papillomavirus type 16 vaccine.

Tammela JE, Lele S, Odunsi K.

N Engl J Med. 2003 Apr 3;348(14):1402-5; author reply 1402-5. No abstract available.

PMID:
12678018
14.

A study of heat shock protein 27 in endometrial carcinoma.

Geisler JP, Geisler HE, Tammela J, Miller GA, Wiemann MC, Zhou Z.

Gynecol Oncol. 1999 Mar;72(3):347-50.

PMID:
10053106
15.

Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma.

Tammela J, Geisler JP, Eskew PN Jr, Geisler HE.

Eur J Gynaecol Oncol. 1998;19(5):438-40.

PMID:
9863906
16.

Heat shock protein 27: an independent prognostic indicator of survival in patients with epithelial ovarian carcinoma.

Geisler JP, Geisler HE, Tammela J, Wiemann MC, Zhou Z, Miller GA, Crabtree W.

Gynecol Oncol. 1998 Apr;69(1):14-6.

PMID:
9570992

Supplemental Content

Loading ...
Support Center